Market Cap
$186.9M
CHRS
Coherus Oncology, Inc.
$1.16 ▲ +0.00%
Prev close $1.16Market cap$186.9M
ConsensusStrong Buy
12-mo target$7.75 (+568.1%)
▲ Bullish
Analyst conviction 8/10
21 New Institutional Positions10 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on CHRS right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (83%)
Inst. Holders
50 funds
Inst. Value
$61.5M
Inst. Activity
21 buys / 10 sells
Social Sentiment
40° Cool
SEC Reports
8
Press Releases
3
Price chart 30d -15.3%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 short_volume
Aug 17, 2026 Press Short Volume: CHRS — 76.6% short (0.5M / 0.7M)
Short: 532,968 | Exempt: 1,000 | TRF Vol: 695,476 | Short Ratio: 76.6% | Off-exchange volume (dark p
Coherus Oncology announced a special dividend of contingent value rights (CVRs) tied to the future sale of its remaining
Impact 4/10
Coherus Oncology announced the release date for its Q2 2026 financial results (August 5, 2026) and scheduled a conferenc
PRESS-RELEASE — Impact 1/10
Jun 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC — ADD
883,454 shares ($1.2M)
Jun 30, 2026 Inst.
Jun 15, 2026 SEC UBS Group AG — ADD
760,358 shares ($1.1M)
Coherus Oncology dismissed Ernst & Young as its independent auditor and appointed PricewaterhouseCoopers, effective June
8-K — Impact 3/10
In Q3 2024, a small group of asset managers increased CHRS holdings by $795K, while Temasek Holdings fully exited a $10.
INST-CLUSTER — Impact 4/10
Jun 5, 2026 Insider
Newton Charles W. was granted 30,000 shares
Director
Analyst ratings buy % +1.2%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
83% rate it Buy or better · 12 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 7, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| May 11, 2026 | Guggenheim | INITIATE | Buy | 52% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Aug 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jul 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| Jun 1, 2026 | 5 | 6 | 2 | 0 | 0 | 85% | |
| May 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Apr 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Mar 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% | |
| Feb 1, 2026 | 4 | 6 | 2 | 0 | 0 | 83% |
Price targets
Where 4 covering analysts think CHRS trades over the next 12 months.
$7.75 +568.1% upside Strong Buy
Current$1.16 Low$4.00 Median$8.50 High$10.00 4 analysts
$4.00$10.00
Analyst rating None as of Oct 2, 2026
Social media sentiment
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
40°
Cool
BearishNeutralBullish
Recent posts
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 1 bullish, 1 bearish, 1 mixed, 5 neutral · avg impact 3.4/10.Plus 3 press releases.
NEUTRALPRESS-RELEASE1/10
Coherus Oncology announced the release date for its Q2 2026 financial results (August 5, 2026) and s
Jul 22, 2026
NEUTRAL8-K3/10
Coherus Oncology dismissed Ernst & Young as its independent auditor and appointed PricewaterhouseCoo
Jun 15, 2026
BEARISHINST-CLUSTER4/10
In Q3 2024, a small group of asset managers increased CHRS holdings by $795K, while Temasek Holdings
Jun 12, 2026
NEUTRALDEFA14A4/10
Coherus Oncology's 2026 annual meeting was adjourned from May 27 to May 29, 2026, to count remaining
May 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 1, 2026
Clinical Trial
Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma
Phase Phase 2 — TERMINATED
Sep 29, 2026
short_volume
Short Volume: CHRS — 76.6% short (0.5M / 0.7M)
Short: 532,968 | Exempt: 1,000 | TRF Vol: 695,476 | Short Ratio: 76.6% | Off-exchange volume (dark pool + OTC)
Sep 25, 2026
short_volume
Short Volume: CHRS — 69.9% short (0.4M / 0.6M)
Short: 424,212 | Exempt: 246 | TRF Vol: 606,728 | Short Ratio: 69.9% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
short_volume
Short Volume: CHRS — 65.8% short (0.5M / 0.8M)
Short: 510,571 | Exempt: 3,191 | TRF Vol: 776,201 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
Sep 23, 2026
other
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - - Oppenheimer Initiates a Robust Process with Global Reac
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.21 | $-0.21–$-0.21 | 36.4% | +6.7% | 2↑ 0↓ | $0.0B | 2 |
| Next Q | $-0.20 | $-0.22–$-0.19 | 39.7% | -36.7% | 1↑ 1↓ | $0.0B | 2 |
| Current FY | $-0.85 | $-0.87–$-0.84 | 37.1% | -14.8% | 1↑ 1↓ | $0.1B | 2 |
| Next FY | $-0.63 | $-0.65–$-0.61 | 26.3% | +38.2% | 1↑ 0↓ | $0.1B | 2 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.210 | — |
| 7d ago | $-0.225 | +0.015 |
| 30d ago | $-0.225 | +0.015 |
| 60d ago | $-0.225 | +0.015 |
| 90d ago | $-0.250 | +0.040 |
Institutional ownership
Which big funds own CHRS (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $61.5M total value (43,886,399 shares) as of 2026-Q2. Top holders: BlackRock,, VANGUARD, GEODE. Net buying activity: 21 institutions added/increased vs 10 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 12,003,316 | $16.8M | 27.3% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 5,949,490 | $8.3M | 13.5% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 3,685,567 | $5.2M | 8.4% | — |
| STATE STREET CORP | 2,382,305 | $3.3M | 5.4% | — |
| TWO SIGMA INVESTMENTS, LP | 2,259,412 | $3.2M | 5.1% | — |
| Alyeska Investment Group, L.P. | 1,733,234 | $2.4M | 3.9% | — |
| Hudson Bay Capital Management LP | 1,693,000 | $2.4M | 3.9% | DOUBLED +104.2% |
| AQR CAPITAL MANAGEMENT LLC | 1,330,201 | $1.9M | 3.0% | ADD +36.2% |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1,228,069 | $1.7M | 2.8% | — |
| PANAGORA ASSET MANAGEMENT INC | 1,137,325 | $1.6M | 2.6% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 604,525 | 883,454 | +46.1% | $1.2M |
| UBS Group AG | ADD | 547,209 | 760,358 | +39.0% | $1.1M |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 331,700 | 563,056 | +69.7% | $788.3K |
| IEQ CAPITAL, LLC | ADD | 121,967 | 162,353 | +33.1% | $227.3K |
| DEUTSCHE BANK AG\ | ADD | 71,762 | 127,621 | +77.8% | $178.7K |
| WELLS FARGO & COMPANY/MN | DOUBLED | 38,639 | 112,903 | +192.2% | $158.1K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | TRIM | 287,500 | 109,627 | -61.9% | $153.5K |
| MetLife Investment Management, LLC | DOUBLED | 39,013 | 78,613 | +101.5% | $110.1K |
| SEI INVESTMENTS CO | NEAR_EXIT | 453,763 | 76,629 | -83.1% | $107.3K |
| Cerity Partners LLC | DOUBLED | 35,968 | 74,607 | +107.4% | $104.5K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 36 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 5, 2026 | Newton Charles W. | Director | AWARD | 30,000 | — | — |
| Jun 5, 2026 | Newton Charles W. | Director | AWARD | 60,000 | — | — |
| Jun 5, 2026 | Wahlstrom Mats | Director | AWARD | 60,000 | — | — |
| Jun 5, 2026 | Wahlstrom Mats | Director | AWARD | 30,000 | — | — |
| Jun 5, 2026 | O'Donnell-Tormey Jill | Director | AWARD | 30,000 | — | — |
| Jun 5, 2026 | O'Donnell-Tormey Jill | Director | AWARD | 60,000 | — | — |
| Jun 5, 2026 | Ryan Michael Lee | Director | AWARD | 30,000 | — | — |
| Jun 5, 2026 | Ryan Michael Lee | Director | AWARD | 60,000 | — | — |
| Jun 5, 2026 | Karachun Rita A | Director | AWARD | 30,000 | — | — |
| Jun 5, 2026 | Karachun Rita A | Director | AWARD | 60,000 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for CHRS.
Shares short
22,848,985
Settlement Sep 15, 2026
Change vs prior
-4.5%
Semi-monthly cycle
Days to cover
32.8
At avg daily volume
Of shares outstanding
≈14.8%
Estimate — not % of float
All CHRS filing & press-release reports (11)
- PRESS-RELEASE reportAug 17, 2026
- PRESS-RELEASE reportJul 22, 2026
- 8-K reportJun 15, 2026
- INST-CLUSTER reportJun 12, 2026
- DEFA14A reportMay 28, 2026
- PRESS-RELEASE reportMay 11, 2026
- DEFA14A reportMay 5, 2026
- PRESS-RELEASE reportMay 4, 2026
- PRESS-RELEASE reportMar 9, 2026
- PRESS-RELEASE reportMar 2, 2026
- INST-CLUSTER reportFeb 28, 2026